TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
His resignation would be effective from March 18, 2024
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
Currently, Venkat is Lead – Market Access, India at Pfizer
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Ronco succeeds Dr. Christine Dingivan, who will now serve as a senior advisor to Executive Chairman Sastry Chilukuri
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
Subscribe To Our Newsletter & Stay Updated
